Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381281 | 0.91 | TRPV1 (0.40) | FFAR1PPARDPPARAPPARGTRPV1 | |
| SCHEMBL5176763 | 0.80 | NLRP3 (0.42) | FFAR1GRM5HAO1ADORA2BMLYCD | |
| SCHEMBL3872102 | 0.80 | PPARD (0.53) | FFAR1PPARDPPARAPPARGMCL1 | |
| SCHEMBL5004274 | 0.75 | NR5A1 (0.40) | FFAR1TRPV1KMT2A | |
| SCHEMBL3873464 | 0.74 | MCL1 (0.44) | FFAR1PPARDPPARAPPARGTRPV1 | |
| SCHEMBL3874608 | 0.74 | FFAR1 (0.67) | FFAR1GRM5HAO1 | |
| SCHEMBL3975113 | 0.71 | PPARD (0.56) | PPARDPPARAPPARGTRPV1MCL1 | |
| SCHEMBL3876123 | 0.71 | TRPV1 (0.43) | PPARDPPARAPPARGTRPV1PLA2G10 | |
| SCHEMBL3871621 | 0.71 | TRPV1 (0.41) | FFAR1PPARDPPARAPPARGTRPV1 | |
| SCHEMBL1382381 | 0.70 | PPARD (0.55) | PPARDPPARAPPARGMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4629106-B2 | — | — | 2011-02-09 | — | — | JP | claimed |
| EP-1781608-B1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | claimed |
| US-7405236-B2 | Indole derivatives comprising an acetylene group | HOFFMAN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | claimed |
| JP-2008509947-A | — | — | 2008-04-03 | — | — | JP | claimed |
| EP-1781608-A1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018174-A1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | claimed |
| US-20060035956-A1 | e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis | HOFFMANN-LA ROCHE INC. | 2006-02-16 | — | — | US | claimed |
| EP-1781608-B1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7405236-B2 | Indole derivatives comprising an acetylene group | HOFFMAN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060035956-A1 | e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis | HOFFMANN-LA ROCHE INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035956-A1 | e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis | PPARD, PPARG, PPARA | FFAR1 5/4885PPARD 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.